UNSPSC 51373002: Bremazocine

This classification denotes an opioid receptor agonist with the molecular formula C20H29NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ISF76M2DBE, chemically known as 2,6-methano-3-benzazocin-8-ol, 6-ethyl-1,2,3,4,5,6-hexahydro-3-((1-hydroxycyclopropyl)methyl)-11,11-dimethyl- but generally known as bremazocine, which bears US NIH Compound Identifier 1223. European Medicines Agency schedules Bremazocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05884MIG.

UNSPSC 51373002 Bremazocine (Commodity tier) does not align with the recent state and local procurement activity tagged under this code. The three most recent opportunities solicited naloxone and drug deactivation systems, therapeutic pharmacy initiatives for direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which are bremazocine or closely related opioid antagonists. The code shows little relevant recent activity under its nominal scope; the opportunities reflect broader pharmaceutical procurement by health agencies rather than procurement specific to bremazocine.

Issuing bodies across the opportunities include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Department of Administration's MMCAP). The geographic spread spans Florida, Texas, and Minnesota with participating jurisdictions including Oregon. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (posted June 30, 2026; due July 26, 2023), the Texas HHS RFI on direct-to-manufacturer prescription programs (posted April 3, 2026; response due April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products across state and local facilities (posted January 20, 2026; proposals due March 26, 2026). Business development professionals should treat this code as misaligned with the pharmaceutical procurement landscape it currently reflects and verify coding accuracy with issuing bodies before pursuing opportunities under this UNSPSC designation.